A reported meta-analysis found that standardized saffron extract produced improvements in depression and anxiety comparable to commonly prescribed antidepressants, although researchers said larger studies are still needed before it can be broadly incorporated into psychiatric treatment.
By yourNEWS Media Newsroom
Saffron extract may reduce symptoms of depression and anxiety as effectively as certain prescription antidepressants while causing fewer unwanted effects, according to a meta-analysis described in a Feb. 12, 2026, report by NaturalNews.com.
The analysis examined findings from multiple clinical trials in which saffron was evaluated either independently or directly compared with selective serotonin reuptake inhibitors, commonly known as SSRIs. The report did not provide the total number of trials or participants included in the analysis.
Across the studies, standardized saffron extract reportedly produced antidepressant and anti-anxiety effects similar to those observed with conventional medications. Participants taking saffron also experienced fewer of the adverse effects commonly associated with antidepressant treatment, according to the report.
Saffron is derived from the stigmas of Crocus sativus, a purple-flowering plant cultivated for culinary and traditional medicinal use. The spice has been used for generations across parts of Asia, Europe, the Middle East and North Africa.
Modern researchers have increasingly focused on saffron’s possible neurological and psychiatric effects, particularly the activity of crocin and safranal, two of its principal compounds.
The meta-analysis found that saffron may influence several of the same chemical pathways targeted by prescription antidepressants. The report said its active compounds appear to increase or prolong the availability of serotonin and dopamine, neurotransmitters involved in mood, motivation and emotional regulation.
SSRIs primarily work by limiting the reabsorption of serotonin, leaving more of the neurotransmitter available between nerve cells. Saffron was reported to produce a related effect while also acting on additional biological systems.
The report said saffron may affect gamma-aminobutyric acid, commonly known as GABA, an inhibitory neurotransmitter associated with relaxation and reduced nervous-system activity. Some prescription anti-anxiety medications also act through GABA-related pathways.
Crocin and safranal may further protect brain cells from oxidative stress and reduce inflammation affecting the nervous system, according to the analysis. Chronic inflammation and oxidative damage have been investigated as possible contributors to depression, particularly in people who do not respond adequately to standard treatments.
The combined influence on serotonin, dopamine, GABA, inflammation and oxidative stress may help explain why saffron has been studied for a broader range of symptoms than depressed mood alone.
Researchers cited in the report associated saffron supplementation with improvements in anxiety, sleep quality, premenstrual mood symptoms and memory among people with mild cognitive concerns. Those outcomes were not described as equally established, however, and the strength of the evidence may differ depending on the condition being studied.
The reported comparison with antidepressants was particularly significant because common psychiatric medications can produce side effects that lead some patients to discontinue treatment.
The analysis said saffron was not associated with the same degree of weight gain, emotional blunting or sexual dysfunction frequently reported by some patients taking antidepressants. That could make the extract a subject of interest for people who cannot tolerate conventional medication, although the findings do not establish that saffron is appropriate for every patient.
Depression and anxiety can vary widely in severity, cause and duration. People experiencing severe symptoms, suicidal thoughts, major functional impairment or rapidly worsening mental health require prompt professional evaluation and should not replace prescribed treatment with a supplement without medical guidance.
The findings were also consistent with a separate 2026 study involving patients with ulcerative colitis, according to NaturalNews.com. That study reportedly found that a higher-dose saffron supplement reduced intestinal inflammation and anxiety symptoms.
The results contributed to growing interest in the relationship between digestive health, inflammation and mental well-being. Researchers continue to investigate whether changes in the gastrointestinal system can influence mood through immune activity, nerve signaling and the gut-brain connection.
Uma Naidoo, author of “This Is Your Brain on Food,” has written about the role nutrients and dietary compounds may play in neurotransmitter production and mood regulation. Her work supports a broader field of nutritional psychiatry that examines how food and nutrient intake may complement conventional mental health care.
Bick Wanck, author of “Mind Easing: The Three-Layered Healing Plan for Anxiety and Depression,” has similarly promoted approaches that address biological and lifestyle factors contributing to emotional symptoms.
Dr. Daniel G. Amen, author of “The End of Mental Illness,” has advocated for treatment strategies that consider nutrition and other health interventions alongside established psychiatric care.
Those perspectives do not establish saffron as a replacement for medication, psychotherapy or other evidence-based treatments, but they reflect a growing interest in combining medical care with nutritional and lifestyle interventions.
The daily amount most commonly associated with favorable results was 30 milligrams of standardized saffron extract, according to the reported analysis. Participants generally used the supplement consistently for at least four to six weeks before researchers assessed the full effect.
The report distinguished standardized extracts from culinary saffron. Small amounts of the spice used in food may not provide the concentration of crocin, safranal or related compounds used in clinical studies.
Consistency was also described as important. Irregular supplementation or products containing inadequate amounts of active compounds may not reproduce the findings observed in controlled trials.
The report suggested consuming saffron with a small quantity of dietary fat to improve absorption. It also discussed combining saffron with magnesium or B vitamins, although the evidence presented did not establish that those combinations are necessary or more effective for every person.
Supplement quality presents another consideration. Standardization helps ensure that a product contains a predictable quantity of the compounds being studied. Products marketed simply as saffron may differ considerably in purity, potency and composition.
Saffron supplements may also interact with medications or be unsuitable for certain individuals. People who are pregnant, have a bleeding disorder, take blood-thinning drugs, use blood pressure medication or receive psychiatric treatment should consult a qualified health professional before beginning concentrated saffron supplementation.
Patients taking antidepressants should be especially cautious about adding any product that may influence serotonin. Combining multiple serotonin-altering substances without supervision can create safety concerns.
The report suggested that saffron’s limited adoption in conventional psychiatry may partly reflect the difficulty of obtaining exclusive patent protection for a naturally occurring plant product. Without the financial incentives associated with patented medications, researchers may face greater challenges securing funding for the large, multicenter clinical trials commonly used to shape medical guidelines.
That explanation remains an interpretation rather than proof that commercial interests alone are responsible for saffron’s limited clinical use. Medical guidelines generally require extensive evidence involving large populations, standardized preparations, long-term safety data and independent replication.
Although the accumulated studies were described as promising, the report acknowledged the need for additional investigation into saffron as both a standalone therapy and an addition to existing treatment.
Future research would need to determine which patients are most likely to benefit, whether effects continue over longer periods and how saffron compares with different medication classes and psychotherapy. Researchers would also need to establish reliable manufacturing and dosing standards.
The available findings suggest that saffron’s mental health effects may extend beyond a single biochemical mechanism. Its apparent activity involving neurotransmitters, inflammation and oxidative stress distinguishes it from treatments designed to act primarily on one pathway.
Still, comparable outcomes in selected trials do not mean saffron and prescription antidepressants are interchangeable in all situations. Clinical decisions depend on symptom severity, medical history, other medications and the patient’s response to previous treatment.
Based on the analysis, a standardized 30-milligram daily extract taken for four to six weeks was the regimen most closely associated with measurable improvements. Researchers characterized the results as evidence supporting further study of saffron for depression and anxiety, particularly among patients who experience significant medication side effects.
The findings add to a developing body of research examining whether a spice traditionally used for centuries could become a carefully regulated component of modern mental health treatment. Larger and more detailed clinical trials will be necessary to determine whether its reported benefits can be consistently reproduced and safely incorporated into routine care.
Explainer Infographic
Comments